Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks™ HT

Journal of Pharmacological and Toxicological Methods

Volumn 54, Issue 2, 2006, Pages 189-199

  Bridgland Taylor, M H ^a   Hargreaves, A C ^a   Easter, A ^a   Orme, A ^a   Henthorn, D C ^a   Ding, M ^b   Davis, A M ^a   Small, B G ^a   Heapy, C G ^a   Abi Gerges, N ^a   Persson, F ^b   Jacobson, I ^b   Sullivan, M ^a   Albertson, N ^b   Hammond, T G ^a   Sullivan, E ^a   Valentin, J P ^a   Pollard, C E ^a  

^a ASTRAZENECA   (United Kingdom)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

hERG; IonWorks HT; Medium throughput; Methods; Rubidium efflux

Indexed keywords

CISAPRIDE; POTASSIUM CHANNEL HERG;

ANIMAL CELL; ARTICLE; CHO CELL; CONTROLLED STUDY; CORRELATION ANALYSIS; ELECTROPHYSIOLOGY; IC 50; METHODOLOGY; NONHUMAN; VALIDATION PROCESS;

ANIMALS; CELL LINE; CHO CELLS; CRICETINAE; ELECTROPHYSIOLOGY; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNEL BLOCKERS; REPRODUCIBILITY OF RESULTS; RUBIDIUM;

EID: 33748129547     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vascn.2006.02.003     Document Type: Article

References (46)

1. Angelo K., Korolkova Y.V., Grunnet M., Grishin E.V., Pluzhnikov K.A., Klaerke D.A., et al. A radiolabeled peptide ligand of the hERG channel, [125I]-BeKm-1. Pflugers Archiv 447 (2003) 55-63
2. Anon. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. ICH E14 (2005) CHMP/ICH/2/04
3. Anon. The nonclinical evaluation of the potential for delayed ventricular repolarisation (QT interval prolongation) by human pharmaceuticals. ICH S7B (2005) CHMP/ICH/423/02
4. Aronov A.M. Predictive in silico modeling for hERG channel blockers. Drug Discovery Today 10 (2005) 149-155
5. Aronov A.M., and Goldman B.B. A model for identifying HERG K(+) channel blockers. Bioorganic & Medicinal Chemistry 12 (2004) 2307-2315
6. Austin R.P., Barton P., Cockroft S.L., Wenlock M.C., and Riley R.J. The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. Drug Metabolism and Disposition 30 (2002) 1497-1503
7. Austin R.P., Barton P., Mohmed S., and Riley R.J. The binding of drugs to hepatocytes and its relationship to physicochemical properties. Drug Metabolism and Disposition 33 (2005) 419-425
8. Bell I.M., Gallicchio S.N., Abrams M., Beshore D.C., Buser C.A., Culberson J.C., et al. Design and biological activity of (S)-4-(5-([1-(3-chlorobenzyl)-2-oxopyrrolidin-3-ylamino]methyl)imidazol- 1-ylmethyl)benzonitrile, a 3-aminopyrrolidinone farnesyltransferase inhibitor with excellent cell potency. Journal of Medicinal Chemistry 44 (2001) 2933-2949
9. Bilodeau M.T., Balitza A.E., Koester T.J., Manley P.J., Rodman L.D., Buser-Doepner C., et al. Potent N-(1,3-thiazol-2-yl)pyridin-2-amine vascular endothelial growth factor receptor tyrosine kinase inhibitors with excellent pharmacokinetics and low affinity for the hERG ion channel. Journal of Medicinal Chemistry 47 (2004) 6363-6372
10. Cavalli A., Poluzzi E., De Ponti F., and Recanatini M. Toward a pharmacophore for drugs inducing the long QT syndrome: Insights from a CoMFA study of HERG K(+) channel blockers. Journal of Medicinal Chemistry 45 (2002) 3844-3853
11. Chen J., Seebohm G., and Sanguinetti M.C. Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and eag potassium channels. Proceedings of the National Academy of Sciences of the United States of America 99 (2002) 12461-12466
12. Chiu P.J., Marcoe K.F., Bounds S.E., Lin C.H., Feng J.J., Lin A., et al. Validation of a [3H]astemizole binding assay in HEK293 cells expressing HERG K+ channels. Journal of Pharmacological Science 95 (2004) 311-319
13. Diaz G.J., Daniell K., Leitza S.T., Martin R.L., Su Z., McDermott J.S., et al. The [3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K+]o. Journal of Pharmacological and Toxicological Methods 50 (2004) 187-199
14. Ekins S. In silico approaches to predicting drug metabolism, toxicology and beyond. Biochemical Society Transactions 31 (2003) 611-614
15. Finlayson K., Turnbull L., January C.T., Sharkey J., and Kelly J.S. [3H]dofetilide binding to HERG transfected membranes: A potential high throughput preclinical screen. European Journal of Pharmacology 430 (2001) 147-148
16. Guo L., and Guthrie H. Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation. Journal of Pharmacological and Toxicological Methods 52 (2005) 123-135
17. Guthrie H., Livingston F.S., Gubler U., and Garippa R. A place for high-throughput electrophysiology in cardiac safety: Screening hERG cell lines and novel compounds with the ion works HTTM system. Journal of Biomolecular Screening 10 (2005) 832-840
18. Kamiya K., Mitcheson J.S., Yasui K., Kodama I., and Sanguinetti M.C. Open channel block of HERG K(+) channels by vesnarinone. Molecular Pharmacology 60 (2001) 244-253
19. Kiesecker C., Zitron E., Luck S., Bloehs R., Scholz E.P., Kathofer S., et al. Class Ia anti-arrhythmic drug ajmaline blocks HERG potassium channels: Mode of action. Naunyn-Schmiedeberg's Archives of Pharmacology 370 (2004) 423-435
20. Mitcheson J.S. Drug binding to HERG channels: Evidence for a 'non-aromatic' binding site for fluvoxamine. British Journal of Pharmacology 139 (2003) 883-884
21. Mitcheson J.S., Chen J., and Sanguinetti M.C. Trapping of a methanesulfonanilide by closure of the HERG potassium channel activation gate. Journal of General Physiology 115 (2000) 229-240
22. Murphy S.M., Palmer M., Poole M.F., Padegimas L., Hunady K., Danzig J., et al. Evaluation of functional and binding assays in cells expressing either recombinant or endogenous hERG channel. Journal of Pharmacological and Toxicological Methods (2005) (epub ahead of print)
23. Netzer R., Bischoff U., and Ebneth A. HTS techniques to investigate the potential effects of compounds on cardiac ion channels at early-stages of drug discovery. Current Opinion in Drug Discovery & Development 6 (2003) 462-469
24. Pearlstein R.A., Vaz R.J., Kang J., Chen X.L., Preobrazhenskaya M., Shchekotikhin A.E., et al. Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches. Bioorganic & Medicinal Chemistry Letters 13 (2003) 1829-1835
25. Pearlstein R., Vaz R., and Rampe D. Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior. Journal of Medicinal Chemistry 46 (2003) 2017-2022
26. Persson F., Carlsson L., Duker G., and Jacobson I. Blocking characteristics of hERG, hNav1.5, and hKvLQT1/hminK after administration of the novel anti-arrhythmic compound AZD7009. Journal of Cardiovascular Electrophysiology 16 (2005) 329-341
27. Po S.S., Wang D.W., Yang I.C., Johnson Jr. J.P., Nie L., and Bennett P.B. Modulation of HERG potassium channels by extracellular magnesium and quinidine. Journal of Cardiovascular Pharmacology 33 (1999) 181-185
28. Rampe D., Roy M.L., Dennis A., and Brown A.M. A mechanism for the proarrhythmic effects of cisapride (Propulsid): High affinity blockade of the human cardiac potassium channel HERG. FEBS Letters 417 (1997) 28-32
29. Redfern W.S., Carlsson L., Davis A.S., Lynch W.G., MacKenzie I., Palethorpe S., et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovascular Research 58 (2003) 32-45
30. Rezazadeh S., Hesketh J.C., and Fedida D. Rb+ flux through hERG channels affects the potency of channel blocking drugs: Correlation with data obtained using a high-throughput Rb+ efflux assay. Journal of Biomolecular Screening 9 (2004) 588-597
31. Roche O., Trube G., Zuegge J., Pflimlin P., Alanine A., and Schneider G. A virtual screening method for prediction of the HERG potassium channel liability of compound libraries. ChemBioChem 3 (2002) 455-459
32. Sanchez-Chapula J.A., Navarro-Polanco R.A., Culberson C., Chen J., and Sanguinetti M.C. Molecular determinants of voltage-dependent human ether-a-go-go related gene (HERG) K+ channel block. Journal of Biological Chemistry 277 (2002) 23587-23595
33. Schroeder K., Neagle B., Trezise D.J., and Worley J. IonWorks HT: A new high-throughput electrophysiology measurement platform. Journal of Biomolecular Screening 8 (2003) 50-64
34. Shah R.R. Drugs, QT interval prolongation and ICH E14: The need to get it right. Drug Safety 28 (2005) 115-125
35. Sorota S., Zhang X.S., Margulis M., Tucker K., and Priestley T. Characterization of a hERG screen using the IonWorks HT: Comparison to a hERG rubidium efflux screen. Assay of Drug Development Technology 3 (2005) 47-57
36. Tang W., Kang J., Wu X., Rampe D., Wang L., Shen H., et al. Development and evaluation of high throughput functional assay methods for HERG potassium channel. Journal of Biomolecular Screening 6 (2001) 325-331
37. Titier K., Canal M., Deridet E., Abouelfath A., Gromb S., Molimard M., et al. Determination of myocardium to plasma concentration ratios of five antipsychotic drugs: Comparison with their ability to induce arrhythmia and sudden death in clinical practice. Toxicology and Applied Pharmacology 199 (2004) 52-60
38. Wang J., Della P.K., Wang H., Karczewski J., Connolly T.M., Koblan K.S., et al. Functional and pharmacological properties of canine ERG potassium channels. American Journal of Physiology. Heart and Circulatory Physiology 284 (2003) H256-H267
39. Waring, M.J. and Johnstone, C. A Quantitative Assessment of hERG Liability as a Function of Lipophilicity. Journal of Medicinal Chemistry (submitted for publication).
40. Weerapura M., Nattel S., Chartier D., Caballero R., and Hebert T.E. A comparison of currents carried by HERG, with and without coexpression of MiRP1, and the native rapid delayed rectifier current. Is MiRP1 the missing link?. Journal of Physiology 540 (2002) 15-27
41. Wible B.A., Hawryluk P., Ficker E., Kuryshev Y.A., Kirsch G., and Brown A.M. HERG-Lite: A novel comprehensive high-throughput screen for drug-induced hERG risk. Journal of Pharmacological and Toxicological Methods 52 (2005) 136-145
42. Witchel H.J., Dempsey C.E., Sessions R.B., Perry M., Milnes J.T., Hancox J.C., et al. The low-potency, voltage-dependent HERG blocker propafenone-molecular determinants and drug trapping. Molecular Pharmacology 66 (2004) 1201-1212
43. Witchel H.J., Milnes J.T., Mitcheson J.S., and Hancox J.C. Troubleshooting problems with in vitro screening of drugs for QT interval prolongation using HERG K+ channels expressed in mammalian cell lines and Xenopus oocytes. Journal of Pharmacological and Toxicological Methods 48 (2002) 65-80
44. Yang T., and Roden D.M. Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence. Circulation 93 (1996) 407-411
45. Zhang S., Zhou Z., Gong Q., Makielski J.C., and January C.T. Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. Circulation Research 84 (1999) 989-998
46. Zhou Z., Vorperian V.R., Gong Q., Zhang S., and January C.T. Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole. Journal of Cardiovascular Electrophysiology 10 (1999) 836-843